Cepheid, a California-based molecular diagnostics company, and the Foundation for Innovative New Diagnostics (FIND) announced a new collaboration to accelerate the development of a rapid HIV viral load test. This viral load test will run on the platform of Cepheid’s GeneXpert, the ground-breaking rapid test to diagnose drug-susceptible and drug-resistant tuberculosis. Given the high rates of TB/HIV co-infection, especially in southern Africa, a diagnostic with both these capabilities could be incredibly beneficial in diagnosing and managing these two deadly infectious diseases. To read the full press announcement, click here.
Community-based and comprehensive, response to HIV among people injecting drugs in Athens reversed climb in new cases
Before 2011, when HIV infections among people who injected drugs in Athens, Greece rose suddenly and steeply, the epidemic of the virus in that country was […]
First year report describes assessments of needs, strategies, opportunities In December 2015, tuberculosis response advocates welcomed the release of a White House National Action Plan for […]
Submissions propose tests to ward of unnecessary, ineffective antibiotic use “Think ‘home pregnancy test’ but for nearly any infectious disease,” — specifically for drug-resistant gonorrhea — one […]
From the rain-soaked National Mall in Washington D.C., to cities across the United States and around the world, on the streets of Cape Town, Kampala, Lagos, […]